Expansion and preferential activation of the CD14+CD16+ monocyte subset during multiple sclerosis
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Multiple sclerosis (MS) is an immune‐driven, demyelinating disease of the central nervous system (CNS). Although many types of immune cells are involved in disease progression, activated monocytes are believed to be one of the first to arrive to the brain and initiate inflammation. However, little is known about how the two main monocyte subsets, CD14++CD16− and CD14+CD16+, are involved in MS. To understand how the phenotype and responses of these monocyte subsets are altered during MS, total monocytes and the purified monocyte subsets from healthy subjects (n=29) and MS patients (n=20) were characterized ex vivo and stimulated in vitro with lipopolysaccharide (LPS). The ex vivo analyses showed that total monocytes from MS patients had significantly elevated levels of CD40, CD86, HLA‐DR, CD64 and C‐C motif chemokine receptor 2 (CCR2), and this elevation was most marked on CD16+ monocytes. In vitro stimulation with LPS led to an increase in CD86, HLA‐DR, CD64 and IL‐6 production by monocytes from MS patients. Furthermore, in purified cultures, CD14+ monocytes were found to be the main producers of IL‐10 while CD16+ monocytes produced more IL‐12. In monocytes from MS patients, both subsets produced substantially more IL‐6, and the production of IL‐10 by the CD16+ subset was also significantly elevated compared with healthy monocytes. Together these findings highlight the important contribution of the CD16+ monocyte subset in driving inflammatory responses during MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Korn, T., Bettelli, E., Oukka, M., & Kuchroo, V. K. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132710 · Cited by 4,873
Exacerbations of multiple sclerosis in patients treated with gamma interferon
Panitch, H., Haley, A., Hirsch, R., & Johnson, K. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92863-7 · Cited by 1,071
Preferential recruitment of interferon‐γ–expressing T H 17 cells in multiple sclerosis
Kebir, H., Ifergan, I., Alvarez, J. I., Bernard, M., Poirier, J., Arbour, N., Duquette, P., & Prat, A. (2009) · Annals of Neurology · doi:10.1002/ana.21748 · Cited by 551
Type II monocytes modulate T cell–mediated central nervous system autoimmune disease
Weber, M. S., Prod'homme, T., Youssef, S., Dunn, S. E., Rundle, C. D., Lee, L., Patarroyo, J. C., Stüve, O., Sobel, R. A., Steinman, L., et al. (2007) · Nature Medicine · doi:10.1038/nm1620 · Cited by 447
Trebst, C., Lykke Sørensen, T., Kivisäkk, P., Cathcart, M. K., Hesselgesser, J., Horuk, R., Sellebjerg, F., Lassmann, H., & Ransohoff, R. M. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63017-9 · Cited by 242
Hill, K. E., Zollinger, L. V., Watt, H. E., Carlson, N. G., & Rose, J. W. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2004.02.005 · Cited by 158
Cited by
Inflammation in multiple sclerosis
Haase, S., & Linker, R. A. (2021) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864211007687 · Cited by 183
Nowak, W., Grendas, L. N., Sanmarco, L. M., Estecho, I. G., Arena, Á. R., Eberhardt, N., Rodante, D. E., Aoki, M. P., Daray, F. M., Carrera Silva, E. A., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.10.063 · Cited by 159
“Moreover a stronger positive correlation was detected with the increased plasma level of IL-12, suggesting a potential link between IL-12 and non-classical monocytes as was suggested by Chuluundorj et al [16].”
BackgroundMunawara, U., Catanzaro, M., Xu, W., Tan, C., Hirokawa, K., Bosco, N., Dumoulin, D., Khalil, A., Larbi, A., Lévesque, S., et al. (2021) · Immunity & Ageing · doi:10.1186/s12979-021-00236-x · Cited by 74
Amoruso, A., Blonda, M., Gironi, M., Grasso, R., Di Francescantonio, V., Scaroni, F., Furlan, R., Verderio, C., & Avolio, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-63282-3 · Cited by 46
Moreno, M. A., Burns, T., Yao, P., Miers, L., Pleasure, D., & Soulika, A. M. (2016) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2015.11.004 · Cited by 34
“Interestingly, it was previously shown that bothmonocytes and neutrophils expand in the blood preclinically in EAE (Rumble et al., 2015) and neutrophil-related chemokines andmonocyte subsets are increased in the blood of MS patients (Chuluundorj et al., 2014; Rumble et al., 2015).”
Background
Metadata
- Authors
- Chuluundorj, D., Harding, S. A., Abernethy, D., & La Flamme, A. C.
- Venue
- Immunology & Cell Biology
- Publisher
- Wiley
- Published
- 2014-03-18
- Volume
- 92
- Issue
- 6
- Pages
- 509-517
- ISSN
- 0004-945X (ISSN-L)
- 0818-9641
- 1440-1711
- OpenAlex
- W2008010286
- Cited by
- 116
- References
- 6
- FWCI
- 5.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Expansion and preferential activation of the CD14+CD16+ monocyte subset during multiple sclerosis. https://app.cochat.ai/papers/10.1038/icb.2014.15
- The paper
- Chuluundorj, D., Harding, S. A., Abernethy, D., & La Flamme, A. C. (2014). Expansion and preferential activation of the CD14+CD16+ monocyte subset during multiple sclerosis. Immunology & Cell Biology. https://doi.org/10.1038/icb.2014.15
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.